Unknown

Dataset Information

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.


ABSTRACT:

Background

The full utility of an acute treatment requires examination of the entire time course of effect during a migraine attack. Here the time course of effect of ubrogepant is evaluated.

Methods

ACHIEVE-I and -II were double-blind, single-attack, Phase 3 trials. Adults with migraine were randomised 1:1:1 to placebo or ubrogepant (50mg or 100mg, ACHIEVE-I; 25 mg or 50 mg, ACHIEVE-II). Pain freedom, absence of most bothersome symptom, and pain relief were assessed at various timepoints. Samples were collected for pharmacokinetic analysis. Data were pooled for this post-hoc analysis.

Results

Participants' (n = 912 placebo, n = 887 ubrogepant 50 mg, pooled analysis population) mean age was 41 years, with a majority female and white. Pain relief separated from

SUBMITTER: Goadsby PJ 

PROVIDER: S-EPMC8047719 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature